You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL

Authors

  • Fengmei Song Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Yongxian Hu Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Yanlei Zhang Shanghai YaKe Biotechnology Ltd, ShanghaiChina PubMed articlesGoogle scholar articles
  • Mingming Zhang Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Tingting Yang Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Wenjun Wu Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Simao Huang Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Huijun Xu Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Alex H Chang Shanghai YaKe Biotechnology Ltd, ShanghaiChinaClinical Transformation Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, ShanghaiChina PubMed articlesGoogle scholar articles
  • He Huang Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles
  • Guoqing Wei Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaLiangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, ChinaInstitute of HematologyZhejiang University, Hangzhou, ChinaZhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China PubMed articlesGoogle scholar articles

Citation

Song F, Hu Y, Zhang Y, et al
Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL
Journal for ImmunoTherapy of Cancer 2023;11:e005701. doi: 10.1136/jitc-2022-005701
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.